For example, FXR and TGR5 agonists have demonstrated preclinical benefits for IBD by regulating intestinal barrier function and suppressing inflammatory responses, making them promising candidates for treating IBD and metabolic disorders (Stepanov et al., 2013). This evidence concerns the gene NR1H4 and inflammatory bowel disease.